MA52939A - Composés inhibiteurs d'oga - Google Patents
Composés inhibiteurs d'ogaInfo
- Publication number
- MA52939A MA52939A MA052939A MA52939A MA52939A MA 52939 A MA52939 A MA 52939A MA 052939 A MA052939 A MA 052939A MA 52939 A MA52939 A MA 52939A MA 52939 A MA52939 A MA 52939A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382455 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52939A true MA52939A (fr) | 2021-04-28 |
Family
ID=62784078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052939A MA52939A (fr) | 2018-06-21 | 2019-06-20 | Composés inhibiteurs d'oga |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210130352A1 (fr) |
| EP (1) | EP3810608B1 (fr) |
| JP (1) | JP2021527687A (fr) |
| CN (1) | CN112313231B (fr) |
| AU (1) | AU2019291099A1 (fr) |
| CA (1) | CA3103048A1 (fr) |
| ES (1) | ES2927355T3 (fr) |
| MA (1) | MA52939A (fr) |
| WO (1) | WO2019243533A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| EP3788053B1 (fr) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| WO2019232419A1 (fr) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP7454572B2 (ja) | 2018-11-19 | 2024-03-22 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| EP3972973A1 (fr) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Formes à l'état solide |
| CA3161156A1 (fr) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthese amelioree de composes inhibiteurs de kras g12c |
| KR20220118484A (ko) * | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | Oga 억제제 화합물 |
| AU2020409728A1 (en) * | 2019-12-18 | 2022-08-11 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| KR20240156373A (ko) | 2022-03-07 | 2024-10-29 | 암젠 인크 | 4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| US20040235867A1 (en) * | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| BRPI0819453A2 (pt) * | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| CN103864793B (zh) * | 2014-03-12 | 2016-08-17 | 山东大学 | 取代嘌呤-9-乙酰氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用 |
| MX381417B (es) * | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| WO2017106254A1 (fr) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Inhibiteurs de glycosidase et leurs utilisations |
| CN108884077A (zh) * | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| US10906900B2 (en) * | 2016-09-26 | 2021-02-02 | Centre National De La Recherche Scientifique | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases |
-
2019
- 2019-06-20 AU AU2019291099A patent/AU2019291099A1/en not_active Abandoned
- 2019-06-20 WO PCT/EP2019/066392 patent/WO2019243533A1/fr not_active Ceased
- 2019-06-20 CN CN201980041370.0A patent/CN112313231B/zh not_active Expired - Fee Related
- 2019-06-20 MA MA052939A patent/MA52939A/fr unknown
- 2019-06-20 JP JP2020570881A patent/JP2021527687A/ja active Pending
- 2019-06-20 US US17/253,522 patent/US20210130352A1/en not_active Abandoned
- 2019-06-20 ES ES19732991T patent/ES2927355T3/es active Active
- 2019-06-20 EP EP19732991.5A patent/EP3810608B1/fr active Active
- 2019-06-20 CA CA3103048A patent/CA3103048A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112313231A (zh) | 2021-02-02 |
| EP3810608B1 (fr) | 2022-08-10 |
| CN112313231B (zh) | 2023-05-09 |
| AU2019291099A1 (en) | 2021-01-07 |
| JP2021527687A (ja) | 2021-10-14 |
| WO2019243533A1 (fr) | 2019-12-26 |
| CA3103048A1 (fr) | 2019-12-26 |
| EP3810608A1 (fr) | 2021-04-28 |
| US20210130352A1 (en) | 2021-05-06 |
| ES2927355T3 (es) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| IL292753A (en) | Compounds | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA52948A (fr) | Composés | |
| EP3941898C0 (fr) | Composés fongicides | |
| EP3737672A4 (fr) | Composés benzamide | |
| IL286833A (en) | Compositions containing brazzein | |
| MA51669A (fr) | Composés | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| MA53003A (fr) | Composés | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA52946A (fr) | Composés | |
| EP3808747A4 (fr) | Composé d'imidazopyridinone | |
| EP4077318A4 (fr) | Composés | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP4003986A4 (fr) | Composés inhibiteurs | |
| EP3833342A4 (fr) | Composés d'imidazotétrazine | |
| LT3867247T (lt) | Naujieji junginiai |